[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"MEDLINE IND\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":74},{"warningLetters":4,"total":73},[5,31,51],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},244,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-25T04:00:00Z\">03\u002F25\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-723866-03252026\">Medline Industries, LP \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Boyle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medline Industries, LP \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Lakes Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60093\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:JBoyle@medline.com\"> JBoyle@medline.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 723866\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 25, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Boyle:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801, from December 1, 2025 through December 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and assembles numerous medical devices into Cardiovascular Procedure Kits to include (but not limited to) NAMIC brand Angiographic Control Syringes and manifolds intended to be used for the intra-arterial or intravenous administration of radiographic contrast media. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mr. Richard Kalita, Senior Manager of Quality Assurance, dated January 13, 2026, and February 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>A. Your firm failed to implement section 5.8.4 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 40), which states “***\u003Cem>[the] degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the problem and commensurate with the risks encountered\u003C\u002Fem>***”, in that your firm did not take actions commensurate with risk for NAMIC Angiographic Control Syringes in the field for which CAPA-01872 was opened due to an increase in complaints in June 2023 regarding disconnection from manifolds you attributed to the presence of excess silicone. Your Health Hazard Evaluation (HHE) Qual-124366 dated June 11, 2024, determined the risk was low, which is inconsistent with your design failure modes and effectiveness analysis (dFMEA) (RA2022047; Rev. 4) which identified \"air embolism\" as the highest severity issue for loose connections. Your firm’s corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 MDRs for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians, including one (1) MDR # 3015910259-2025-00109 involving the injection of air into a patient (Complaint # \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and one (1) MDR # 3015910259-2024-00045 involving biohazard exposure of a clinician (Complaint # \u003Cstrong>(b)(4)\u003C\u002Fstrong> dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>B. Your firm failed to implement section 5.19 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 47; Effective: 11\u002F1\u002F25), in that “***\u003Cem>while in the effectiveness check stage and either the effectiveness check failed or additional root causes or problems are identified; the CAPA may be routed back to a previous phase or an additional CAPA may be opened at the discretion of the CRB [CAPA Review Board]. Risk and containment activities must be considered when moving the CAPA to a previous phase\u003C\u002Fem>***”. Your firm did not execute any of the above actions for CAPA-01872 when trending data revealed, as early as Quarter 1 of 2025, that the complaints per million (CPM) of NAMIC Angiographic Control Syringes manufactured post-corrective action was at 16.90 CPM followed by 16.44 CPM in Quarter 2 and 26.81 CPM in Quarter 3, all of which was above the 15.98 CPM threshold for complaints received for disconnections established in the verification of effectiveness plan (VOE AI# \u003Cstrong>(b)(4)\u003C\u002Fstrong> to start 1\u002F15\u002F25; Updated 8\u002F1\u002F25). Moreover, the total rate of complaints, including devices manufactured before and after the implementation of the corrective action (starting January 15, 2025) and for product where the manufacturing date is unknown, was 39.95 CPM, 31.62 CPM, and 59.27 CPM for Quarters 1, 2 and 3 of 2025, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, your firm acknowledged that the corrective action was not effective, closed CAPA-01872, and opened a new CAPA-02612 to further investigate the issue. You also communicate a plan to issue a field correction with a safety notice to all customers who have received or will receive NAMIC Angiographic Control Syringes, based on a HHE (Qual-156459) of post-market data from June 2023 to December 2025, to alert them about the unwinding issue and provide reinforced instructions and additional guidance. You further state that you plan to develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringe solution currently undergoing verification with production targeted to begin in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and proposed that a field notice rather than a full product removal was appropriate given the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage.\u003C\u002Fp>\u003Cp>In your latest response on February 27, 2026, you state that you updated your HHE (Qual-156459; Approved 2\u002F26\u002F26) to reflect your revised plan to conduct a removal of NAMIC Angiographic Control Syringes based on multiple discussions with the agency regarding your recall strategy. This HHE reports a total CPM for the syringe\u002F manifold disconnection issue from June 2023 to February 19, 2026, as 62.62 CPM (250 complaints out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes manufactured ending \u003Cstrong>(b)(4)\u003C\u002Fstrong>). On March 13, 2026, an 806 Report was submitted to the agency for the removal of these devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cp>You also indicate that you initiated an additional CAPA-02627 under which you conducted a systemic review of all open CAPAs and trained personnel on an updated CAPA procedure (SOP-00022) which requires more frequent post-market data reviews per established guidance. The targeted completion date for CAPA-02627 is June 30, 2026.\u003C\u002Fp>\u003Cp>With regards to CAPA-02612, no information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue. Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective. Furthermore, the manufacturing quantities documented in your updated HHE fall short of the nearly \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes your Senior Director of Quality stated were manufactured (approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and nearly \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>) in that it states that only \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringes were manufactured through \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulting in 62.62 CPM (250 complaints), without defining the manufacturing start date of affected products. The HHE also incorrectly specifies a corrective action start date of June 2024 instead of April 16, 2024, as specified in CAPA-01872.\u003C\u002Fp>\u003Cp>With regards to CAPA-02627, you did not identify actions that assure that employees will follow your corrective action procedure to route the CAPA back to a previous phase or open an additional CAPA as soon as it is evident that corrective actions are not effective, as was the case in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of 2025 when your complaint analysis data showed that the CPM for syringe and manifold disconnections was above the established CPM thresholds.\u003C\u002Fp>\u003Cp>Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to implement sections 6.2.2 (\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning) and 6.3 (General Requirements) of your “GN 010 - Manufacturing Cleaning Procedure” (NMC-00228; Rev. 7; Effective: 5\u002F2\u002F25) which state “\u003Cem>a top-to-bottom cleaning of the controlled environments will be conducted, at minimum, \u003Cstrong>(b)(4)\u003C\u002Fstrong>***The cleaning shall also include all equipment not routinely cleaned by operators***” and “***Always clean the \u003Cstrong>(b)(4)\u003C\u002Fstrong> first and work toward the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of cleaning with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> being last\u003C\u002Fem>***,” respectively, of controlled environments such as the clean rooms where you manufacture various Angiographic and Radiology Syringes. In addition, the corresponding forms titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Schedule and Sign-off Sheet” form (NMC-00228-F-00001; Rev. 2) and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Schedule and Sign-off Sheet” (NMC-00228-F-00002; Rev.1) are inadequate because they fail to ensure consistent implementation of sections 6.2.2 and 6.3 of NMC-00228 due to absence of specific instructions requiring the cleaning of top of manufacturing equipment as is included for the cleaning of vents, ceiling lights, walls, benches, cabinets, fixtures, etc. For example, on December 1, 2025, the investigator observed a visible accumulation of particulate on the top of manufacturing equipment in cleanrooms including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringe manufacturing machine (ID # 90303527), \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (ID # 90306846), \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing machine (ID # 90308616), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machine (Asset # 8974). There have been approximately 114 complaints regarding foreign matter or hair in the package or device from December 2023 to at least December 1, 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, you state you performed immediate ad-hoc cleaning of all equipment to remove observed particulate matter, established preventative maintenance schedules based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> of monitoring data, and updated the cleaning and preventative maintenance procedures (NMC-00228 and NMC-00171) to formalize these requirements followed by training under CAPA-02518. Additionally, you state you developed an ad-hoc cleaning procedure (NMC-01120) and addressed air filtration concerns by installing \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicators around all cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> vents to ensure proper clearance, repaired damaged vents, and updated your environmental control procedure (NMC-00233) to include inspection and clearance requirements. You also determined that validation of the cleaning process was not required.\u003C\u002Fp>\u003Cp>In your latest response on February 27, 2026, you state you conducted a comprehensive review of the cleanroom manufacturing environments and identified improvement opportunities but not any risks. The target completion for these additional actions is April 30, 2026, and the target completion date of CAPA-02518 is July 17, 2026.\u003C\u002Fp>\u003Cp>However, there were no corrective actions identified to assess the impact of products in the field and inventory for products which have been manufactured in these cleanrooms since the last documented cleaning of equipment tops on November 26, 2023, including review of the manufacturing dates of products referenced in the 114 complaints received for foreign matter or hair since this date as a part of the respective complaint investigations. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for verifying the device design. Design verification shall confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\u003C\u002Fp>\u003Cp>Specifically, your firm’s design verification conducted under “Design Verification Protocol Polycarbonate Female Luer ISO 80369-7” (P017333; Rev. B; Approved: 10\u002F7\u002F20) with resulting “Design Verification Report Polycarbonate Female Luer ISO 80369-7” (P017334; Rev. A; Approved: 6\u002F30\u002F20) fails to demonstrate that the polycarbonate female luer connector components of your Fluid Management product lines (e.g., stopcock product family, manifold product family, disposable transducer product family, Y adaptor, etc.), which underwent changes to their threads and taper dimensions to become BS EN ISO 80369-7 compliant, meet the dimensional and functional testing requirements specified in this standard. For example, there was no documentation in the protocol (or elsewhere) on why design verification testing was only performed on a single female luer connector (Part # 24644210) and not any of the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> connectors listed in the “Scope” section of this protocol which were also impacted by this design change. Moreover, this solely tested connector is not included in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) which captures all luer connectors affected by this design change.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026 response, you state you revised the design verification procedure (NMC-00155) to require documentation of part selection rationale, added product configuration tables and guidance for recording representative SKU selection and rationale for selection in the Design Verification Protocol Template (NMC-00155-F-00001), and amended design change file QUAL-66717 to include the missing justification for part selection under CAPA-02610.\u003C\u002Fp>\u003Cp>In your latest response on February 27, 2026, you state you conducted a comprehensive review of all design changes from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to present that required design verification testing and uncovered four (4) instances of insufficient documentation of part rationale which will require protocol updates with appropriate justification. The target completion of CAPA-02610 is June 1, 2026.\u003C\u002Fp>\u003Cp>However, review of the “Unit Rationale” provided revealed that it fails to explain how design verification testing of part number 41338202 covers anything beyond the manifold product family, such as the stopcock product family, disposable transducer product family, and Y adaptor of the Fluid Management product lines which were in the scope of the Design Verification. Moreover, this rationale does not explain why this part number was not listed in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) meant to capture all the luer connectors affected by this design change. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on December 1, 2025 to December 12, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723866” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Bradley R. Pratt, Sr. Director of Manufacturing Operations, BPratt@medline.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJim Boyle\n\nRecipient Title\n\nCEO\n\nMedline Industries, LP\n\n3 Lakes Drive\n\nNorthfield, IL 60093\n\nUnited States\n\nJBoyle@medline.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 723866\nMarch 25, 2026\nDear Mr. Boyle:\nDuring an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801, from December 1, 2025 through December 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and assembles numerous medical devices into Cardiovascular Procedure Kits to include (but not limited to) NAMIC brand Angiographic Control Syringes and manifolds intended to be used for the intra-arterial or intravenous administration of radiographic contrast media. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mr. Richard Kalita, Senior Manager of Quality Assurance, dated January 13, 2026, and February 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically:\nA. Your firm failed to implement section 5.8.4 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 40), which states “***[the] degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the problem and commensurate with the risks encountered***”, in that your firm did not take actions commensurate with risk for NAMIC Angiographic Control Syringes in the field for which CAPA-01872 was opened due to an increase in complaints in June 2023 regarding disconnection from manifolds you attributed to the presence of excess silicone. Your Health Hazard Evaluation (HHE) Qual-124366 dated June 11, 2024, determined the risk was low, which is inconsistent with your design failure modes and effectiveness analysis (dFMEA) (RA2022047; Rev. 4) which identified \"air embolism\" as the highest severity issue for loose connections. Your firm’s corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the (b)(4) machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 MDRs for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians, including one (1) MDR # 3015910259-2025-00109 involving the injection of air into a patient (Complaint # (b)(4) dated (b)(4)) and one (1) MDR # 3015910259-2024-00045 involving biohazard exposure of a clinician (Complaint # (b)(4) dated (b)(4)).\nB. Your firm failed to implement section 5.19 of your “Internal Corrective-Preventive Action Procedure (CAPA)” (SOP-00022; Rev. 47; Effective: 11\u002F1\u002F25), in that “***while in the effectiveness check stage and either the effectiveness check failed or additional root causes or problems are identified; the CAPA may be routed back to a previous phase or an additional CAPA may be opened at the discretion of the CRB [CAPA Review Board]. Risk and containment activities must be considered when moving the CAPA to a previous phase***”. Your firm did not execute any of the above actions for CAPA-01872 when trending data revealed, as early as Quarter 1 of 2025, that the complaints per million (CPM) of NAMIC Angiographic Control Syringes manufactured post-corrective action was at 16.90 CPM followed by 16.44 CPM in Quarter 2 and 26.81 CPM in Quarter 3, all of which was above the 15.98 CPM threshold for complaints received for disconnections established in the verification of effectiveness plan (VOE AI# (b)(4) to start 1\u002F15\u002F25; Updated 8\u002F1\u002F25). Moreover, the total rate of complaints, including devices manufactured before and after the implementation of the corrective action (starting January 15, 2025) and for product where the manufacturing date is unknown, was 39.95 CPM, 31.62 CPM, and 59.27 CPM for Quarters 1, 2 and 3 of 2025, respectively.\nWe reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, your firm acknowledged that the corrective action was not effective, closed CAPA-01872, and opened a new CAPA-02612 to further investigate the issue. You also communicate a plan to issue a field correction with a safety notice to all customers who have received or will receive NAMIC Angiographic Control Syringes, based on a HHE (Qual-156459) of post-market data from June 2023 to December 2025, to alert them about the unwinding issue and provide reinforced instructions and additional guidance. You further state that you plan to develop (b)(4) syringe solution currently undergoing verification with production targeted to begin in (b)(4) and proposed that a field notice rather than a full product removal was appropriate given the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage.\nIn your latest response on February 27, 2026, you state that you updated your HHE (Qual-156459; Approved 2\u002F26\u002F26) to reflect your revised plan to conduct a removal of NAMIC Angiographic Control Syringes based on multiple discussions with the agency regarding your recall strategy. This HHE reports a total CPM for the syringe\u002F manifold disconnection issue from June 2023 to February 19, 2026, as 62.62 CPM (250 complaints out of (b)(4) syringes manufactured ending (b)(4)). On March 13, 2026, an 806 Report was submitted to the agency for the removal of these devices ((b)(4)).\nYou also indicate that you initiated an additional CAPA-02627 under which you conducted a systemic review of all open CAPAs and trained personnel on an updated CAPA procedure (SOP-00022) which requires more frequent post-market data reviews per established guidance. The targeted completion date for CAPA-02627 is June 30, 2026.\nWith regards to CAPA-02612, no information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue. Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective. Furthermore, the manufacturing quantities documented in your updated HHE fall short of the nearly (b)(4) syringes your Senior Director of Quality stated were manufactured (approximately (b)(4) devices from (b)(4) to (b)(4) and nearly (b)(4) devices from (b)(4) to (b)(4)) in that it states that only (b)(4) syringes were manufactured through (b)(4), resulting in 62.62 CPM (250 complaints), without defining the manufacturing start date of affected products. The HHE also incorrectly specifies a corrective action start date of June 2024 instead of April 16, 2024, as specified in CAPA-01872.\nWith regards to CAPA-02627, you did not identify actions that assure that employees will follow your corrective action procedure to route the CAPA back to a previous phase or open an additional CAPA as soon as it is evident that corrective actions are not effective, as was the case in (b)(4) of 2025 when your complaint analysis data showed that the CPM for syringe and manifold disconnections was above the established CPM thresholds.\nPlease provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).\nSpecifically, your firm failed to implement sections 6.2.2 ((b)(4) Cleaning) and 6.3 (General Requirements) of your “GN 010 - Manufacturing Cleaning Procedure” (NMC-00228; Rev. 7; Effective: 5\u002F2\u002F25) which state “a top-to-bottom cleaning of the controlled environments will be conducted, at minimum, (b)(4)***The cleaning shall also include all equipment not routinely cleaned by operators***” and “***Always clean the (b)(4) first and work toward the (b)(4) of cleaning with the (b)(4) being last***,” respectively, of controlled environments such as the clean rooms where you manufacture various Angiographic and Radiology Syringes. In addition, the corresponding forms titled “(b)(4) Cleaning Schedule and Sign-off Sheet” form (NMC-00228-F-00001; Rev. 2) and “(b)(4) Cleaning Schedule and Sign-off Sheet” (NMC-00228-F-00002; Rev.1) are inadequate because they fail to ensure consistent implementation of sections 6.2.2 and 6.3 of NMC-00228 due to absence of specific instructions requiring the cleaning of top of manufacturing equipment as is included for the cleaning of vents, ceiling lights, walls, benches, cabinets, fixtures, etc. For example, on December 1, 2025, the investigator observed a visible accumulation of particulate on the top of manufacturing equipment in cleanrooms including the (b)(4) syringe manufacturing machine (ID # 90303527), (b)(4) machine (ID # 90306846), (b)(4) manufacturing machine (ID # 90308616), and (b)(4) machine (Asset # 8974). There have been approximately 114 complaints regarding foreign matter or hair in the package or device from December 2023 to at least December 1, 2025.\nWe reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026, response, you state you performed immediate ad-hoc cleaning of all equipment to remove observed particulate matter, established preventative maintenance schedules based on (b)(4) of monitoring data, and updated the cleaning and preventative maintenance procedures (NMC-00228 and NMC-00171) to formalize these requirements followed by training under CAPA-02518. Additionally, you state you developed an ad-hoc cleaning procedure (NMC-01120) and addressed air filtration concerns by installing (b)(4) indicators around all cleanroom (b)(4) vents to ensure proper clearance, repaired damaged vents, and updated your environmental control procedure (NMC-00233) to include inspection and clearance requirements. You also determined that validation of the cleaning process was not required.\nIn your latest response on February 27, 2026, you state you conducted a comprehensive review of the cleanroom manufacturing environments and identified improvement opportunities but not any risks. The target completion for these additional actions is April 30, 2026, and the target completion date of CAPA-02518 is July 17, 2026.\nHowever, there were no corrective actions identified to assess the impact of products in the field and inventory for products which have been manufactured in these cleanrooms since the last documented cleaning of equipment tops on November 26, 2023, including review of the manufacturing dates of products referenced in the 114 complaints received for foreign matter or hair since this date as a part of the respective complaint investigations. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to establish and maintain procedures for verifying the device design. Design verification shall confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\nSpecifically, your firm’s design verification conducted under “Design Verification Protocol Polycarbonate Female Luer ISO 80369-7” (P017333; Rev. B; Approved: 10\u002F7\u002F20) with resulting “Design Verification Report Polycarbonate Female Luer ISO 80369-7” (P017334; Rev. A; Approved: 6\u002F30\u002F20) fails to demonstrate that the polycarbonate female luer connector components of your Fluid Management product lines (e.g., stopcock product family, manifold product family, disposable transducer product family, Y adaptor, etc.), which underwent changes to their threads and taper dimensions to become BS EN ISO 80369-7 compliant, meet the dimensional and functional testing requirements specified in this standard. For example, there was no documentation in the protocol (or elsewhere) on why design verification testing was only performed on a single female luer connector (Part # 24644210) and not any of the other (b)(4) connectors listed in the “Scope” section of this protocol which were also impacted by this design change. Moreover, this solely tested connector is not included in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) which captures all luer connectors affected by this design change.\nWe reviewed your firm’s response and conclude that it is not adequate. In your January 13, 2026 response, you state you revised the design verification procedure (NMC-00155) to require documentation of part selection rationale, added product configuration tables and guidance for recording representative SKU selection and rationale for selection in the Design Verification Protocol Template (NMC-00155-F-00001), and amended design change file QUAL-66717 to include the missing justification for part selection under CAPA-02610.\nIn your latest response on February 27, 2026, you state you conducted a comprehensive review of all design changes from (b)(4) to present that required design verification testing and uncovered four (4) instances of insufficient documentation of part rationale which will require protocol updates with appropriate justification. The target completion of CAPA-02610 is June 1, 2026.\nHowever, review of the “Unit Rationale” provided revealed that it fails to explain how design verification testing of part number 41338202 covers anything beyond the manifold product family, such as the stopcock product family, disposable transducer product family, and Y adaptor of the Fluid Management product lines which were in the scope of the Design Verification. Moreover, this rationale does not explain why this part number was not listed in the final version of your “Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4” (Approved: 9\u002F7\u002F22) meant to capture all the luer connectors affected by this design change. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on December 1, 2025 to December 12, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 723866” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Bradley R. Pratt, Sr. Director of Manufacturing Operations, BPratt@medline.com","Medline Industries, LP","medline-industries-lp-723866-03252026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-723866-03252026","2026-10-26T08:09:23.493183+00:00","Warning Letter","Issued","2026-04-07","723866","Medical Devices","Jim Boyle","2026-08-19T04:49:13.251+00:00","VIA Electronic Mail","2026-03-25",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":16,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1558,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2024-03-19T17:50:00Z\">03\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-18T04:00:00Z\">03\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-677545-03182024\">Medline Industries, LP\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Boyle\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medline Industries, LP\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Lakes Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60093-2753\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# (677545)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 18, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Boyle:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 3 Lakes Drive, Northfield, IL on December 11, 2023, through January 22, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and complaint file establishment of sterile and bulk non-sterile syringes, needles for human and veterinary use under the Medline brand, and sterile convenience kits used in operating rooms. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response(s) from Joseph Zeman dated February 12, 2024, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the \u003Cem>MEDLINE SYRINGES, MULTIPLE\u003C\u002Fem> and the Jiangsu Shenli Medical Production Co. Ltd. Piston syringes of the sizes and configurations listed in \u003Cstrong>Table 1\u003C\u002Fstrong>, which you include in convenience kits, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring&nbsp;premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at&nbsp;http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Model #\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Item Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Model #\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Item Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83077\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 30ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91839\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83078\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 30ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91840\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83079\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 60ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91841\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83080\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 60ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91842\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL PURPLE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83081\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91845\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL BLUE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83082\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91846\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83083\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91847\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83084\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91849\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83085\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91850\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83087\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FS\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91851\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED HEPARIN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83088\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91852\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL YELLOW NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>83089\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 1ML TB\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91854\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91820\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91855\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW HEP\u002FSALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91821\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91856\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91822\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 3ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91857\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL GREEN CONT\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91825\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91858\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL WHITE SALINE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91826\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91859\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL PURPLE NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91827\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91863\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91828\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91866\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL RED NITRO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91829\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91867\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 5ML L\u002FL BLUE HEPARIN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91830\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91872\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91831\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91873\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL WHITE LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91832\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91874\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FS RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91833\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91876\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL YEL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91834\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL YELLOW\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91877\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FIL YELLOW LIDO\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91835\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91878\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10 ML L\u002FL RED\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91836\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL GREEN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91879\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL GRN\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91837\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91880\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR CNTRL 10ML L\u002FL BLUE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91838\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 20ML L\u002FL WHITE\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>SYR 10ML L\u002FL CONTROL\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\t\u003Ctd>&nbsp;\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cstrong>Table 1.\u003C\u002Fstrong> List of Jiangsu Shenli Medical Production Co. Ltd. Piston syringe configurations implicated in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Specifically, during our inspection:\u003C\u002Fp>\n\n\u003Cp>1. The Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe (5cc Luer Lock) was cleared under K103830. The intended use of the Jiangsu Shenli Medical Production Co., Ltd. 5cc luer lock piston syringe is to inject fluids into or withdraw fluids from the body. Based on FDA's evaluation of your firm's activities, there is evidence that your firm is engaged in the distribution of these Jiangsu Shenli syringes for use within the United States, including as part of convenience kits, with substantially different technological characteristics, namely sizes other than 5 mL, luer slip instead of luer lock tips, syringes intended for specific drugs, different colors (i.e., colorants), and control syringes, each of which constitute a significant change or modification in design that could significantly alter the safety or effectiveness of the device. For further explanation on the need for a new premarket notification, or “510(k),” for changes to the intended use or design affecting safety and effectiveness, it is recommended that you consult the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (fda.gov).” In the guidance at Figure 3 – Flowchart B: Technology, Engineering, and Performance Changes, FDA explains why changes in size, color, specific drug indications and connector type all constitute a major change or modification to the device’s intended use, for which there is not clearance or approval.\u003C\u002Fp>\n\n\u003Cp>As discussed above the products listed in \u003Cstrong>Table 1\u003C\u002Fstrong> are misbranded because there are one or more change(s) or modification(s) to each device that could significantly affect the safety or effectiveness of the devices you have purchased from the manufacturer, Jiangsu Shenli, despite the manufacturer not submitting a 510(k) to FDA. Specifically, changing the volume of the syringe, switching from a luer lock to a luer slip syringe tip, and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing, a leaking device, a higher risk of inappropriate needle detachment, and incorrect device handling. Furthermore, the addition of color additives to the syringe could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure. Labeling the syringe for a specific drug can also cause harm because differences in drug viscosities impact the function of the syringe and can result in patient harm such as inaccurate dosing or incorrect drug usage.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Our inspection revealed multiple customer complaints regarding quality issues (e.g. cracks, breakage during use) for syringes in your surgical kits that include syringes supplied by Jiangsu Shenli Medical Production Co. Ltd that you failed to properly investigate.\u003C\u002Fp>\n\n\u003Cp>Your response dated February 12, 2024, is not adequate. The response indicates you plan to implement further supplier agreements and that you completed a vendor audit for Jiangsu Shenli on February 5, 2024. The findings and outcome of the vendor audit are unclear because you did not provide the complete report. The proposed procedural changes to your vendor evaluation procedure are insufficient because they continue to place all responsibility on the suppliers to claim premarket clearance without you confirming that such clearance exists and is appropriate for device(s) provided by the vendor. It also unclear when these procedures would be implemented and which suppliers they would apply to. Moreover, these procedures would not have detected that K103830 does not permit marketing of syringes other than what was cleared (i.e., 5 mL luer lock syringes). Your response also states you have ceased purchasing syringes from Jiangsu Shenli until they receive appropriate marketing clearance (i.e., a new 510(k)); however, you have not taken action sufficient to mitigate the risks for US consumers related to these violative syringes. For example, you have not committed to recalling and\u002For removing these violative syringes on the US market, not using any violative syringes already in transit from Jiangsu Shenli to Medline, and not using any violative syringes already received by Medline (e.g., in Mexico for inclusion into Medline convenience kits) but yet to be distributed to US customers. Therefore, the proposed corrections are inadequate.\u003C\u002Fp>\n\n\u003Cp>2. During our inspection, we collected documents used to support changes you made to your 510(k) \u003Cem>\u003Cstrong>MEDLINE SYRINGES, MULTIPLE (K061275)\u003C\u002Fstrong>\u003C\u002Fem>, such as the Regulatory Assessment of Change (RAC) K061275-03. The RAC K061275-03 document approved Jiangsu Caina Medical Co Ltd (“Jiangsu Caina”) “as an additional contract manufacturer and contract sterilizer” in China for Medline’s 1 mL luer lock and 1 mL luer slip syringes. In your FDA 483 response to Observation 5 from February 12, 2024, you referenced the flowcharts in FDA guidance, “Deciding When to Submit a 510(k) for a Change to an Existing Device” (available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F99812\u002Fdownload) for this change. In decision point B5.4 “Do design verification and\u002For validation activities produce any unexpected issues of safety or effectiveness?”, you indicated “No.” However, review of your RAC K061275-03 documents demonstrates that this decision was incorrect because the testing had unexpected and unexplained failures.\u003C\u002Fp>\n\n\u003Cp>Specifically, you conducted assessments of the Jiangsu Caina 1mL luer lock and luer slip syringes according to ISO 7886-1 in report “L18-215 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1” and report “L18-216 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101020 1 mL Luer Slip Syringes per ISO 7886-1.” You noted that 55% and 75% of test samples respectively failed when testing the “Tolerance on Graduated Capacity” for delivering 0.2 mL of fluid. You opened an investigation, TOOS18-014, but no further documentation describing the outcome of the investigation was provided. In report “L18-215 – Addendum – 01 Final Report” (dated March 7, 2019) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1”, you stated for the “Tolerance on Graduated Capacity” testing that “the original method did not account for the dead space of the syringe. Therefore, specimens needed to be retested with the correct procedure.” However, “Tolerance on Capacity Testing” per ISO 7886-1:2017 (and as described in section 9.2 of your procedure LAB-00107 Rev. 10) already accounts for dead space, and you still observed a failure rate of 5% among test samples for delivering 0.2 mL of fluid in “L18-215 – Addendum – 01 Final Report” for the 1 mL luer lock syringes. In “MGT - Study Inspection and Status Report”, the “Findings” and “Recommended Actions” sections of each report contain the same handwritten notes saying, “Testing completed as expected” and “None,” respectively, despite seeing failures in the testing. These reports were signed and approved prior to conducting the testing. You then repeated only the “Tolerance on Graduated Capacity” testing in “L21-002 Final Report” (dated January 25, 2021) and reported passing results for all test samples. Your documentation does not contain details of a root cause analysis for the failures observed in the “Tolerance on Graduated Capacity” testing in 2018 and 2019 nor an acceptable rationale for invalidating these test results, whether any changes were made to improve the performance of the syringes between 2019 and 2021 as a result of a root cause analysis, and it does not contain a justification why the testing completed in 2018 and 2019 could be leveraged to support the performance of the syringes tested in 2021. Despite these observations, on January 28, 2021 and January 29, 2021, you finalized RAC K061275-03 document noting, “results from test reports did not produce any unexpected issues of safety or effectiveness.” This statement is incorrect since your performance testing showed unexpected and unexplained failures. Your testing documentation does not support that the modified syringes can successfully deliver accurate volumes across the full range of their claimed graduated capacity. The inability of these syringes to deliver the intended dose could lead to administering syringe content in excess of the intended dose and thus lead to harm to patients. Therefore, your change in manufacturing process (i.e., approving Jiangsu Caina as a manufacturer and sterilizer) could significantly affect the safety or effectiveness of the device. Per 21 CFR 807.81(a)(3)(i) a premarket notification was required before introducing the device into commercial distribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR Part 820.\u003C\u002Fp>\n\n\u003Cp>These violations include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes, as required by part 21 CFR 820.30(i). Specifically,\u003C\u002Fp>\n\n\u003Cp>A. Your firm has not adequately implemented “Corporate Design Control Procedure”, SOP-00050, Rev.13 which states:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. in step 11.3 that “All design changes must be verified and\u002For validated unless proper justification is given as to why verification or validation is unnecessary.” On or about January 31, 2018, Medline approved a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. However, your firm’s risk assessment for the dimensional changes to the syringes does not adequately address identified hazards (i.e., cracked syringes or plunger pullout) or support that the changes would mitigate the risk by reducing the probability of the hazard occurring and would not significantly affect the safety or effectiveness of the piston syringes. A user validation was not performed to confirm the dimensional changes did not adversely affect use of the piston syringes. Your firm’s RAC notes that this is not considered a major change and that verification performance\u002Fbench testing was sufficient to support your firm’s assessment that a new 510(k) was not required as it did not impact safety and effectiveness of syringes.\u003C\u002Fp>\n\n\u003Cp>ii. in step 6.1 “Design reviews may be held at other times throughout the design and development process, including addressing ambiguous data (e.g., inputs, validation activities etc.)”. For example, the Revised Specifications of piston syringes for K061275, as they relate to Design transfer agreement and current contract manufacturing specifications for the manufacturing of these piston syringes include conflicting or ambiguous dimensional specification requirements. The manufacturing dimensional specifications used by your contract manufacturers do not correspond with dimensional changes approved in Regulatory Assessment Change (RAC), K061275. This may adversely impact product quality based on variations from the approved specification and the current contract manufacturing specifications.\u003C\u002Fp>\n\n\u003Cp>B. You firm was unable to provide our investigators with a completed “Product Change Notice and QA Approval Form” for RAC 061275-01 as required by “Corporate Design Control Procedure”, SOP-00050 step 11.2. According to the procedure, design changes are to be documented on a Product Change Notice and QA Approval Form which are also design control requirements set forth under 21 CFR 820.30(i) and (j). The RAC K061275-01 was initiated for “…dimensional changes to increase the wall thickness, edit the taper of the barrel and the retention ring to improve the user experience by reducing&nbsp;the chance for cracked syringes and plunger pullout.” Your firm did not include an assessment of any new risks as part of the dimensional changes as required by the Product Change Notice and QA Approval Form. In addition, section 11.7.1 of the procedure notes that the Change Verification and Validation section of the Product Change and QA Approval Form should be utilized to determine whether or not verification and\u002For validation are required for approval of the proposed change(s). The procedure further states “Should verification and\u002For validation be required, divisional QA must make sure that all supporting documentation, results, justification, etc. are available and attached with form”.\u003C\u002Fp>\n\n\u003Cp>Validation of the design change to support a reduction in cracked syringes and plunger pullout was not performed prior to the implementation and release of product into distribution. In addition, you did not update the design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 and application failures mode and effects analysis (aFMEA) SOP-00099-F-00005 for barrel breakage for the Medline piston syringe (K061275). Your firm continues to receive complaints related to cracked syringes or plunger issues in addition to leaks and breakage during use.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that you have undertaken corrective actions to address the issue with Design Control procedures (design change, design transfer, design change forms), design change form to support the K061275-01 design change and perform an evaluation of design changes to K061275 syringes. These actions encompass conducting a retrospective review of design changes of non-syringe design history files to assure no similar deficiencies exist, updating risk management files, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, the “Complaint Handling and Evaluation” procedure, CHP-00001 has not been adequately implemented to ensure:\u003C\u002Fp>\n\n\u003Cp>A. Complaints are evaluated to determine whether they are events that are required to be reported to FDA. For example,\u003C\u002Fp>\n\n\u003Cp>i. the complaint handling procedure states that a regulatory investigation is required for Medline labeled or branded product complaints that occur during patient use and\u002For cause an adverse reaction or injury. Our investigator noted 16 of 20 complaints did not have a regulatory investigation as required:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Complaint Number\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Notification Date\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Complaint Description\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200391920\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>06\u002F24\u002F2020\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Shattered syringe, piece almost went into surgeon’s hand\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200430173\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>02\u002F23\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringe broke off inside stent connector\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200439795\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>04\u002F21\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881 syringe broke when surgeon started to push in medication; ring on plunger broke off, small plastic piece broke off; very sharp piece and if it went into the abdomen, it would not be found by x-ray. Very dangerous; other syringes have broken, too.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200446540\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>06\u002F04\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringes crack and squirt fluids in the CCL during procedures; one exploded with blood in it.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200477084\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>01\u002F12\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Particles found in packaging…can ruin patient’s one chance at treatment\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200558997\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>05\u002F16\u002F2023\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringes broke during use\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200546695\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>03\u002F03\u002F2023 \u002F [02\u002F15\u002F2023 email sent by customer]\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>91881C seems very cheap, breaking or not working when trying to use\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200441924\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>05\u002F04\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringes cracked, medicine going everywhere\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200438138\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>04\u002F09\u002F2021\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Surgery has found syringes leaking during use\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200392513\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>06\u002F26\u002F2020\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Tabs have been breaking off causing surgeon’s gloves to tear\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200488141\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>03\u002F22\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Needles not locking with syringe and leaking Botox out\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200507995\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>07\u002F18\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Particles found in syringe\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200530846\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>11\u002F28\u002F2022\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringe cracked down the middle when using.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200546698\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>02\u002F08\u002F2023\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Control syringe is unsafe and comes apart.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200550282\u003Cbr>\n\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>03\u002F27\u002F2023\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>“We have been having issues with these syringes. The needle is not well attached and as we draw up sedation with it, we have been losing the sedation and having to waste the meds. It is possible to have the needle on tight so that it does not have to be checked every time. It could also lead to a needle stick if not careful.”\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>200361247\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>01\u002F03\u002F2020\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>[customer] found a hair wrapped around the Syringe Control 10ML product inside this pack.\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>ii. complaint handling procedure Step 5.4.2 states that “…various “key words” and phrases are used to help determine if complaint is a potentially reportable event. The procedure provides key words and phrases that include but are not limited to… Bleeding, Broken components used on a patient, Cut, Exploded, Needle stick, Severe reaction (requiring a medical intervention), Surgery…”. However, 13 of 16 complaints reviewed by our investigator included these key words or phrases and were not evaluated to determine whether the event was reportable to the FDA.\u003C\u002Fp>\n\n\u003Cp>iii. complaints of medical device malfunctions which if they were to recur would likely cause or contribute to a death or serious injury are not evaluated to determine if such event are required to be reported to FDA as a medical device report as required by 21 CFR 820.198(a)(3). In cases where you specified that a clinical review was not required an adequate justification for not performing was included.\u003C\u002Fp>\n\n\u003Cp>B. All complaints are reviewed and evaluated to determine if investigation is necessary and complaints not needing an investigation shall be maintained with the reason for no investigation along with the name of the individual responsible for the decision.\u003C\u002Fp>\n\n\u003Cp>i. There is no written procedure to define the coding that is selected by the complaint handling personnel. Inaccurate coding of the failure or defect will affect the quality data source analysis and may prevent action(s) being taken when necessary.\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; a. 15 of 20 complaints reviewed by our investigator during the inspection were incorrectly coded as needle defects or parts\u002Fcomponents instead of syringe.\u003Cbr>\n&nbsp; &nbsp; b. Complaints listing multiple failed units are counted as one complaint, for trending and analysis.\u003Cbr>\n&nbsp; &nbsp; c. The procedure is lacking other common key words to help determine reportability such as\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Cracks\u003C\u002Fli>\n\t\u003Cli>Dislodgement of the needle from the syringe\u003C\u002Fli>\n\t\u003Cli>Contamination\u003C\u002Fli>\n\t\u003Cli>Particulates\u003C\u002Fli>\n\t\u003Cli>Out of specification syringes (markings dead space, not fitting, deformation)\u003C\u002Fli>\n\t\u003Cli>Leaks\u003C\u002Fli>\n\t\u003Cli>Blockage, foreign material stuck in the syringe.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>ii. Our investigator noted that 16 of 20 complaints reviewed for syringe malfunctions or failures complaints were not evaluated or investigated in accordance with your firm’s written procedure “Finished Device Alleged Failure Investigation”, SOP-00031. According to step 3.2.1.3, the following methods are to be used when completing complaint investigations:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; a. DHR reviews\u003Cbr>\n&nbsp; &nbsp; b. Review of product change notifications\u003Cbr>\n&nbsp; &nbsp; c. Label and or instructions for use review to ensure necessary instructions\u002Fcomplications are complete.\u003Cbr>\n&nbsp; &nbsp; d. Review of inspection reports\u003Cbr>\n&nbsp; &nbsp; e. BOM review\u003C\u002Fp>\n\n\u003Cp>Finished Device Alleged Failure Investigation Procedure SOP-00031 Rev. 21 (the version reviewed during the inspection) required that: “During the complaint investigation process, any\u002Fall applicable investigation methods listed above should be used until the complaint is confirmed.” The result of the investigation methods should be documented within the complaint. If none of the methods can be utilized, a justification\u002Frationale shall be documented in the investigation. A detailed conclusion must be provided.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue of complaint handling, MDR evaluation and determination, complaint coding, and investigations. These actions encompass conducting a retrospective review of complaints (syringe and non-syringe), revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. Your firm’s response does not address the multiple complaints contained within each complaint as this can adversely affect their trending and analysis. Further, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventative actions, as required by part 21 CFR 820.100.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not adequately implemented your written procedure “Internal Corrective-Preventive Action Procedure”, SOP-00022, to analyze quality data such as customer complaints in order to identify existing and potential causes of nonconforming product or other quality problems in order to correct and prevent their recurrence. A review of quality data by our investigator noted approximately 2300 syringe complaints between 2020 and 2023 that were either confirmed or not confirmed, for all syringe types (e.g., bulb syringes, feeding syringes, flush syringes, piston syringes etc.) and other OEM syringes. Your firm’s procedure states in step 5.2, that Medline assesses “…quality data on an on-going basis from both a risk and systemic standpoint using appropriate statistical methodology and analysis.” No trend has been identified for piston syringes by defect group\u002Ffailure code as defined by your firm for any of the following:\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Defect Group\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Number of Complaints\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Needles\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>122\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Particulate\u002FContamination\u002FStains\u002FSpots\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>148\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Parts and Components Issues\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>333\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Syringe\u002FSyringe Damaged\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>129\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>Assembly Issue\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>225\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Cp>\u003Cstrong>Short Text for Cause Code\u003C\u002Fstrong>\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>\n\t\t\t\u003Ctable>\n\t\t\t\t\u003Ctbody>\n\t\t\t\t\t\u003Ctr>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>MFG: Environmental controls\u003Cbr>\n\t\t\t\t\t\t&nbsp;\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>127\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\u003C\u002Ftr>\n\t\t\t\t\t\u003Ctr>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>MFG: Assembly\u002FHuman Error\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>213\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\u003C\u002Ftr>\n\t\t\t\t\t\u003Ctr>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>Customer: Knowledge (Use Error)\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\t\u003Ctd>\n\t\t\t\t\t\t\u003Cp>71\u003C\u002Fp>\n\t\t\t\t\t\t\u003C\u002Ftd>\n\t\t\t\t\t\u003C\u002Ftr>\n\t\t\t\t\u003C\u002Ftbody>\n\t\t\t\u003C\u002Ftable>\n\n\t\t\t\u003Cp>&nbsp;\u003C\u002Fp>\n\t\t\t\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>In addition, your firm’s procedure states in section 5.3 that “there may be a scenario where it is appropriate to initiate a CAPA based on one quality event (e.g. one complaint, one MDR, one recall, one external audit observation, etc.) …. decisions should be commensurate with risk, including the extent of action required to address the quality event.”. Your firm’s management stated that there has not been one quality event in the three years of data reviewed for piston syringes that has resulted in CAPA.\u003C\u002Fp>\n\n\u003Cp>During the inspection our investigator noted that you initiated a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. Your firm’s management explained to our investigator that the RAC was an improvement and enhancement and not done to improve clinical outcomes, mitigate a known risk, or in response to an adverse event. Your firm’s design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 for Medline piston syringe (K061275) lists among other things, piston syringes dimensions and fit as having an impact on product quality and functionality.\u003C\u002Fp>\n\n\u003Cp>The DFMEA indicates that performance testing and finished product testing have reduced the risk as low as possible however your firm continues to receive complaints for loss of primary function among others. All complaints cannot be attributed to application user failures described in your firm’s application failure mode and effects analysis (aFMEA) SOP-00099-F-00005 for Medline piston syringe (K061275).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with CAPA procedures. These actions encompass conducting a retrospective review of complaints, a reanalysis of complaints, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s Vendor Evaluation Procedure SOP-00003 has not been adequately established or maintained to ensure requirements, including quality requirements have been met by suppliers and contractors. For example, the Vendor Evaluation - Supplier Disposition Form for supplier “S” lacks a documented review of marketing clearance for products you distribute and\u002For further manufacture. There is no objective evidence to support the quality agreement requirement “Supplier shall only supply product to Medline that has the appropriate marketing clearance.”\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with purchasing controls to include revisions to purchasing control procedures, employee training, retrospective review of all Medline-branded syringes and syringe kit components, performing a review of active Medline-branded medical devices (non-syringes) and submitting a new 510(k) Premarket Notification for all sizes\u002Fmodels of Medline Piston Syringes. Additionally, corrective actions are being created within the CAPA system for the observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 677545 when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Rafael Padilla at 312-596-4212 or Rafael.padilla@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medial Device and Radiological Health\u003Cbr>\nOperations (OMDRHO) Division 2 Central\u003C\u002Fp>\n\n\u003Cp>And\u003Cbr>\n\u003Cbr>\nKellie B. Kelm, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJames Boyle\n\nRecipient Title\n\nCEO\n\nMedline Industries, LP\n\n3 Lakes Drive\n\nNorthfield, IL 60093-2753\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS# (677545)\n\nMarch 18, 2024\n\nDear Mr. Boyle:\n\nDuring an inspection of your firm located at 3 Lakes Drive, Northfield, IL on December 11, 2023, through January 22, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer and complaint file establishment of sterile and bulk non-sterile syringes, needles for human and veterinary use under the Medline brand, and sterile convenience kits used in operating rooms. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response(s) from Joseph Zeman dated February 12, 2024, concerning our investigators’ observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nUnapproved Device Violations\n\nOur inspection revealed that the MEDLINE SYRINGES, MULTIPLE and the Jiangsu Shenli Medical Production Co. Ltd. Piston syringes of the sizes and configurations listed in Table 1, which you include in convenience kits, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\n\nModel #\n\nItem Description\n\nModel #\n\nItem Description\n\n83077\n\nSYR 30ML L\u002FS\n\n91839\n\nSYR 20ML L\u002FL YELLOW\n\n83078\n\nSYR 30ML L\u002FL\n\n91840\n\nSYR 3ML L\u002FL PURPLE\n\n83079\n\nSYR 60ML L\u002FS\n\n91841\n\nSYR 5ML L\u002FL PURPLE\n\n83080\n\nSYR 60ML L\u002FL\n\n91842\n\nSYR 10ML L\u002FL PURPLE\n\n83081\n\nSYR 10ML L\u002FS\n\n91845\n\nSYR 20ML L\u002FL BLUE SALINE\n\n83082\n\nSYR 10ML L\u002FL\n\n91846\n\nSYR 10ML L\u002FL YELLOW CONT\n\n83083\n\nSYR 3ML L\u002FS\n\n91847\n\nSYR 10ML L\u002FL BLUE LIDO\n\n83084\n\nSYR 3ML L\u002FL\n\n91849\n\nSYR 10ML L\u002FL BLUE SALINE\n\n83085\n\nSYR 5ML L\u002FS\n\n91850\n\nSYR 10ML L\u002FL RED LIDO\n\n83087\n\nSYR 20ML L\u002FS\n\n91851\n\nSYR 10ML L\u002FL RED HEPARIN\n\n83088\n\nSYR 20ML L\u002FL\n\n91852\n\nSYR 5ML L\u002FL YELLOW NITRO\n\n83089\n\nSYR 1ML TB\n\n91854\n\nSYR 10ML L\u002FL YELLOW LIDO\n\n91820\n\nSYR 3ML L\u002FL RED\n\n91855\n\nSYR 10ML L\u002FL YELLOW HEP\u002FSALINE\n\n91821\n\nSYR 3ML L\u002FL GREEN\n\n91856\n\nSYR 10ML L\u002FL RED CONT\n\n91822\n\nSYR 3ML L\u002FL BLUE\n\n91857\n\nSYR 10ML L\u002FL GREEN CONT\n\n91825\n\nSYR 5ML L\u002FL RED\n\n91858\n\nSYR 20ML L\u002FL WHITE SALINE\n\n91826\n\nSYR 5ML L\u002FL GREEN\n\n91859\n\nSYR 5ML L\u002FL PURPLE NITRO\n\n91827\n\nSYR 5ML L\u002FL BLUE\n\n91863\n\nSYR 20ML L\u002FL YELLOW LIDO\n\n91828\n\nSYR 5ML L\u002FL WHITE\n\n91866\n\nSYR 5ML L\u002FL RED NITRO\n\n91829\n\nSYR 5ML L\u002FL YELLOW\n\n91867\n\nSYR 5ML L\u002FL BLUE HEPARIN\n\n91830\n\nSYR 10ML L\u002FL RED\n\n91872\n\nSYR 10ML L\u002FS BLUE\n\n91831\n\nSYR 10ML L\u002FL GREEN\n\n91873\n\nSYR 10ML L\u002FL WHITE LIDO\n\n91832\n\nSYR 10ML L\u002FL BLUE\n\n91874\n\nSYR 10ML L\u002FS RED\n\n91833\n\nSYR 10ML L\u002FL WHITE\n\n91876\n\nSYR CNTRL 10ML L\u002FL YEL\n\n91834\n\nSYR 10ML L\u002FL YELLOW\n\n91877\n\nSYR CNTRL 10ML L\u002FIL YELLOW LIDO\n\n91835\n\nSYR 20ML L\u002FL RED\n\n91878\n\nSYR CNTRL 10 ML L\u002FL RED\n\n91836\n\nSYR 20ML L\u002FL GREEN\n\n91879\n\nSYR CNTRL 10ML L\u002FL GRN\n\n91837\n\nSYR 20ML L\u002FL BLUE\n\n91880\n\nSYR CNTRL 10ML L\u002FL BLUE\n\n91838\n\nSYR 20ML L\u002FL WHITE\n\n91881\n\nSYR 10ML L\u002FL CONTROL\n\nTable 1. List of Jiangsu Shenli Medical Production Co. Ltd. Piston syringe configurations implicated in this Warning Letter.\n\nSpecifically, during our inspection:\n\n1. The Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe (5cc Luer Lock) was cleared under K103830. The intended use of the Jiangsu Shenli Medical Production Co., Ltd. 5cc luer lock piston syringe is to inject fluids into or withdraw fluids from the body. Based on FDA's evaluation of your firm's activities, there is evidence that your firm is engaged in the distribution of these Jiangsu Shenli syringes for use within the United States, including as part of convenience kits, with substantially different technological characteristics, namely sizes other than 5 mL, luer slip instead of luer lock tips, syringes intended for specific drugs, different colors (i.e., colorants), and control syringes, each of which constitute a significant change or modification in design that could significantly alter the safety or effectiveness of the device. For further explanation on the need for a new premarket notification, or “510(k),” for changes to the intended use or design affecting safety and effectiveness, it is recommended that you consult the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (fda.gov).” In the guidance at Figure 3 – Flowchart B: Technology, Engineering, and Performance Changes, FDA explains why changes in size, color, specific drug indications and connector type all constitute a major change or modification to the device’s intended use, for which there is not clearance or approval.\n\nAs discussed above the products listed in Table 1 are misbranded because there are one or more change(s) or modification(s) to each device that could significantly affect the safety or effectiveness of the devices you have purchased from the manufacturer, Jiangsu Shenli, despite the manufacturer not submitting a 510(k) to FDA. Specifically, changing the volume of the syringe, switching from a luer lock to a luer slip syringe tip, and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing, a leaking device, a higher risk of inappropriate needle detachment, and incorrect device handling. Furthermore, the addition of color additives to the syringe could result in adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure. Labeling the syringe for a specific drug can also cause harm because differences in drug viscosities impact the function of the syringe and can result in patient harm such as inaccurate dosing or incorrect drug usage.\n\nYour firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Our inspection revealed multiple customer complaints regarding quality issues (e.g. cracks, breakage during use) for syringes in your surgical kits that include syringes supplied by Jiangsu Shenli Medical Production Co. Ltd that you failed to properly investigate.\n\nYour response dated February 12, 2024, is not adequate. The response indicates you plan to implement further supplier agreements and that you completed a vendor audit for Jiangsu Shenli on February 5, 2024. The findings and outcome of the vendor audit are unclear because you did not provide the complete report. The proposed procedural changes to your vendor evaluation procedure are insufficient because they continue to place all responsibility on the suppliers to claim premarket clearance without you confirming that such clearance exists and is appropriate for device(s) provided by the vendor. It also unclear when these procedures would be implemented and which suppliers they would apply to. Moreover, these procedures would not have detected that K103830 does not permit marketing of syringes other than what was cleared (i.e., 5 mL luer lock syringes). Your response also states you have ceased purchasing syringes from Jiangsu Shenli until they receive appropriate marketing clearance (i.e., a new 510(k)); however, you have not taken action sufficient to mitigate the risks for US consumers related to these violative syringes. For example, you have not committed to recalling and\u002For removing these violative syringes on the US market, not using any violative syringes already in transit from Jiangsu Shenli to Medline, and not using any violative syringes already received by Medline (e.g., in Mexico for inclusion into Medline convenience kits) but yet to be distributed to US customers. Therefore, the proposed corrections are inadequate.\n\n2. During our inspection, we collected documents used to support changes you made to your 510(k) MEDLINE SYRINGES, MULTIPLE (K061275), such as the Regulatory Assessment of Change (RAC) K061275-03. The RAC K061275-03 document approved Jiangsu Caina Medical Co Ltd (“Jiangsu Caina”) “as an additional contract manufacturer and contract sterilizer” in China for Medline’s 1 mL luer lock and 1 mL luer slip syringes. In your FDA 483 response to Observation 5 from February 12, 2024, you referenced the flowcharts in FDA guidance, “Deciding When to Submit a 510(k) for a Change to an Existing Device” (available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F99812\u002Fdownload) for this change. In decision point B5.4 “Do design verification and\u002For validation activities produce any unexpected issues of safety or effectiveness?”, you indicated “No.” However, review of your RAC K061275-03 documents demonstrates that this decision was incorrect because the testing had unexpected and unexplained failures.\n\nSpecifically, you conducted assessments of the Jiangsu Caina 1mL luer lock and luer slip syringes according to ISO 7886-1 in report “L18-215 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1” and report “L18-216 Final Report” (dated October 3, 2018) titled “Performance Evaluation of Caina SYR101020 1 mL Luer Slip Syringes per ISO 7886-1.” You noted that 55% and 75% of test samples respectively failed when testing the “Tolerance on Graduated Capacity” for delivering 0.2 mL of fluid. You opened an investigation, TOOS18-014, but no further documentation describing the outcome of the investigation was provided. In report “L18-215 – Addendum – 01 Final Report” (dated March 7, 2019) titled “Performance Evaluation of Caina SYR101010 1 mL Luer Lock Syringes per ISO 7886-1”, you stated for the “Tolerance on Graduated Capacity” testing that “the original method did not account for the dead space of the syringe. Therefore, specimens needed to be retested with the correct procedure.” However, “Tolerance on Capacity Testing” per ISO 7886-1:2017 (and as described in section 9.2 of your procedure LAB-00107 Rev. 10) already accounts for dead space, and you still observed a failure rate of 5% among test samples for delivering 0.2 mL of fluid in “L18-215 – Addendum – 01 Final Report” for the 1 mL luer lock syringes. In “MGT - Study Inspection and Status Report”, the “Findings” and “Recommended Actions” sections of each report contain the same handwritten notes saying, “Testing completed as expected” and “None,” respectively, despite seeing failures in the testing. These reports were signed and approved prior to conducting the testing. You then repeated only the “Tolerance on Graduated Capacity” testing in “L21-002 Final Report” (dated January 25, 2021) and reported passing results for all test samples. Your documentation does not contain details of a root cause analysis for the failures observed in the “Tolerance on Graduated Capacity” testing in 2018 and 2019 nor an acceptable rationale for invalidating these test results, whether any changes were made to improve the performance of the syringes between 2019 and 2021 as a result of a root cause analysis, and it does not contain a justification why the testing completed in 2018 and 2019 could be leveraged to support the performance of the syringes tested in 2021. Despite these observations, on January 28, 2021 and January 29, 2021, you finalized RAC K061275-03 document noting, “results from test reports did not produce any unexpected issues of safety or effectiveness.” This statement is incorrect since your performance testing showed unexpected and unexplained failures. Your testing documentation does not support that the modified syringes can successfully deliver accurate volumes across the full range of their claimed graduated capacity. The inability of these syringes to deliver the intended dose could lead to administering syringe content in excess of the intended dose and thus lead to harm to patients. Therefore, your change in manufacturing process (i.e., approving Jiangsu Caina as a manufacturer and sterilizer) could significantly affect the safety or effectiveness of the device. Per 21 CFR 807.81(a)(3)(i) a premarket notification was required before introducing the device into commercial distribution.\n\nQuality System Regulation Violations\n\nOur inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR Part 820.\n\nThese violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes, as required by part 21 CFR 820.30(i). Specifically,\n\nA. Your firm has not adequately implemented “Corporate Design Control Procedure”, SOP-00050, Rev.13 which states:\n\ni. in step 11.3 that “All design changes must be verified and\u002For validated unless proper justification is given as to why verification or validation is unnecessary.” On or about January 31, 2018, Medline approved a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. However, your firm’s risk assessment for the dimensional changes to the syringes does not adequately address identified hazards (i.e., cracked syringes or plunger pullout) or support that the changes would mitigate the risk by reducing the probability of the hazard occurring and would not significantly affect the safety or effectiveness of the piston syringes. A user validation was not performed to confirm the dimensional changes did not adversely affect use of the piston syringes. Your firm’s RAC notes that this is not considered a major change and that verification performance\u002Fbench testing was sufficient to support your firm’s assessment that a new 510(k) was not required as it did not impact safety and effectiveness of syringes.\n\nii. in step 6.1 “Design reviews may be held at other times throughout the design and development process, including addressing ambiguous data (e.g., inputs, validation activities etc.)”. For example, the Revised Specifications of piston syringes for K061275, as they relate to Design transfer agreement and current contract manufacturing specifications for the manufacturing of these piston syringes include conflicting or ambiguous dimensional specification requirements. The manufacturing dimensional specifications used by your contract manufacturers do not correspond with dimensional changes approved in Regulatory Assessment Change (RAC), K061275. This may adversely impact product quality based on variations from the approved specification and the current contract manufacturing specifications.\n\nB. You firm was unable to provide our investigators with a completed “Product Change Notice and QA Approval Form” for RAC 061275-01 as required by “Corporate Design Control Procedure”, SOP-00050 step 11.2. According to the procedure, design changes are to be documented on a Product Change Notice and QA Approval Form which are also design control requirements set forth under 21 CFR 820.30(i) and (j). The RAC K061275-01 was initiated for “…dimensional changes to increase the wall thickness, edit the taper of the barrel and the retention ring to improve the user experience by reducing the chance for cracked syringes and plunger pullout.” Your firm did not include an assessment of any new risks as part of the dimensional changes as required by the Product Change Notice and QA Approval Form. In addition, section 11.7.1 of the procedure notes that the Change Verification and Validation section of the Product Change and QA Approval Form should be utilized to determine whether or not verification and\u002For validation are required for approval of the proposed change(s). The procedure further states “Should verification and\u002For validation be required, divisional QA must make sure that all supporting documentation, results, justification, etc. are available and attached with form”.\n\nValidation of the design change to support a reduction in cracked syringes and plunger pullout was not performed prior to the implementation and release of product into distribution. In addition, you did not update the design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 and application failures mode and effects analysis (aFMEA) SOP-00099-F-00005 for barrel breakage for the Medline piston syringe (K061275). Your firm continues to receive complaints related to cracked syringes or plunger issues in addition to leaks and breakage during use.\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that you have undertaken corrective actions to address the issue with Design Control procedures (design change, design transfer, design change forms), design change form to support the K061275-01 design change and perform an evaluation of design changes to K061275 syringes. These actions encompass conducting a retrospective review of design changes of non-syringe design history files to assure no similar deficiencies exist, updating risk management files, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\n2. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, the “Complaint Handling and Evaluation” procedure, CHP-00001 has not been adequately implemented to ensure:\n\nA. Complaints are evaluated to determine whether they are events that are required to be reported to FDA. For example,\n\ni. the complaint handling procedure states that a regulatory investigation is required for Medline labeled or branded product complaints that occur during patient use and\u002For cause an adverse reaction or injury. Our investigator noted 16 of 20 complaints did not have a regulatory investigation as required:\n\nComplaint Number\n\nNotification Date\n\nComplaint Description\n\n200391920\n\n06\u002F24\u002F2020\n\nShattered syringe, piece almost went into surgeon’s hand\n\n200430173\n\n02\u002F23\u002F2021\n\nSyringe broke off inside stent connector\n\n200439795\n\n04\u002F21\u002F2021\n\n91881 syringe broke when surgeon started to push in medication; ring on plunger broke off, small plastic piece broke off; very sharp piece and if it went into the abdomen, it would not be found by x-ray. Very dangerous; other syringes have broken, too.\n\n200446540\n\n06\u002F04\u002F2021\n\nSyringes crack and squirt fluids in the CCL during procedures; one exploded with blood in it.\n\n200477084\n\n01\u002F12\u002F2022\n\nParticles found in packaging…can ruin patient’s one chance at treatment\n\n200558997\n\n05\u002F16\u002F2023\n\nSyringes broke during use\n\n200546695\n\n03\u002F03\u002F2023 \u002F [02\u002F15\u002F2023 email sent by customer]\n\n91881C seems very cheap, breaking or not working when trying to use\n\n200441924\n\n05\u002F04\u002F2021\n\nSyringes cracked, medicine going everywhere\n\n200438138\n\n04\u002F09\u002F2021\n\nSurgery has found syringes leaking during use\n\n200392513\n\n06\u002F26\u002F2020\n\nTabs have been breaking off causing surgeon’s gloves to tear\n\n200488141\n\n03\u002F22\u002F2022\n\nNeedles not locking with syringe and leaking Botox out\n\n200507995\n\n07\u002F18\u002F2022\n\nParticles found in syringe\n\n200530846\n\n11\u002F28\u002F2022\n\nSyringe cracked down the middle when using.\n\n200546698\n\n02\u002F08\u002F2023\n\nControl syringe is unsafe and comes apart.\n\n200550282\n\n03\u002F27\u002F2023\n\n“We have been having issues with these syringes. The needle is not well attached and as we draw up sedation with it, we have been losing the sedation and having to waste the meds. It is possible to have the needle on tight so that it does not have to be checked every time. It could also lead to a needle stick if not careful.”\n\n200361247\n\n01\u002F03\u002F2020\n\n[customer] found a hair wrapped around the Syringe Control 10ML product inside this pack.\n\nii. complaint handling procedure Step 5.4.2 states that “…various “key words” and phrases are used to help determine if complaint is a potentially reportable event. The procedure provides key words and phrases that include but are not limited to… Bleeding, Broken components used on a patient, Cut, Exploded, Needle stick, Severe reaction (requiring a medical intervention), Surgery…”. However, 13 of 16 complaints reviewed by our investigator included these key words or phrases and were not evaluated to determine whether the event was reportable to the FDA.\n\niii. complaints of medical device malfunctions which if they were to recur would likely cause or contribute to a death or serious injury are not evaluated to determine if such event are required to be reported to FDA as a medical device report as required by 21 CFR 820.198(a)(3). In cases where you specified that a clinical review was not required an adequate justification for not performing was included.\n\nB. All complaints are reviewed and evaluated to determine if investigation is necessary and complaints not needing an investigation shall be maintained with the reason for no investigation along with the name of the individual responsible for the decision.\n\ni. There is no written procedure to define the coding that is selected by the complaint handling personnel. Inaccurate coding of the failure or defect will affect the quality data source analysis and may prevent action(s) being taken when necessary.\n\na. 15 of 20 complaints reviewed by our investigator during the inspection were incorrectly coded as needle defects or parts\u002Fcomponents instead of syringe.\n\nb. Complaints listing multiple failed units are counted as one complaint, for trending and analysis.\n\nc. The procedure is lacking other common key words to help determine reportability such as\n\nCracks\n\nDislodgement of the needle from the syringe\n\nContamination\n\nParticulates\n\nOut of specification syringes (markings dead space, not fitting, deformation)\n\nLeaks\n\nBlockage, foreign material stuck in the syringe.\n\nii. Our investigator noted that 16 of 20 complaints reviewed for syringe malfunctions or failures complaints were not evaluated or investigated in accordance with your firm’s written procedure “Finished Device Alleged Failure Investigation”, SOP-00031. According to step 3.2.1.3, the following methods are to be used when completing complaint investigations:\n\na. DHR reviews\n\nb. Review of product change notifications\n\nc. Label and or instructions for use review to ensure necessary instructions\u002Fcomplications are complete.\n\nd. Review of inspection reports\n\ne. BOM review\n\nFinished Device Alleged Failure Investigation Procedure SOP-00031 Rev. 21 (the version reviewed during the inspection) required that: “During the complaint investigation process, any\u002Fall applicable investigation methods listed above should be used until the complaint is confirmed.” The result of the investigation methods should be documented within the complaint. If none of the methods can be utilized, a justification\u002Frationale shall be documented in the investigation. A detailed conclusion must be provided.\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue of complaint handling, MDR evaluation and determination, complaint coding, and investigations. These actions encompass conducting a retrospective review of complaints (syringe and non-syringe), revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. Your firm’s response does not address the multiple complaints contained within each complaint as this can adversely affect their trending and analysis. Further, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventative actions, as required by part 21 CFR 820.100.\n\nSpecifically, your firm has not adequately implemented your written procedure “Internal Corrective-Preventive Action Procedure”, SOP-00022, to analyze quality data such as customer complaints in order to identify existing and potential causes of nonconforming product or other quality problems in order to correct and prevent their recurrence. A review of quality data by our investigator noted approximately 2300 syringe complaints between 2020 and 2023 that were either confirmed or not confirmed, for all syringe types (e.g., bulb syringes, feeding syringes, flush syringes, piston syringes etc.) and other OEM syringes. Your firm’s procedure states in step 5.2, that Medline assesses “…quality data on an on-going basis from both a risk and systemic standpoint using appropriate statistical methodology and analysis.” No trend has been identified for piston syringes by defect group\u002Ffailure code as defined by your firm for any of the following:\n\nDefect Group\n\nNumber of Complaints\n\nNeedles\n\n122\n\nParticulate\u002FContamination\u002FStains\u002FSpots\n\n148\n\nParts and Components Issues\n\n333\n\nSyringe\u002FSyringe Damaged\n\n129\n\nAssembly Issue\n\n225\n\nShort Text for Cause Code\n\nMFG: Environmental controls\n\n127\n\nMFG: Assembly\u002FHuman Error\n\n213\n\nCustomer: Knowledge (Use Error)\n\n71\n\nIn addition, your firm’s procedure states in section 5.3 that “there may be a scenario where it is appropriate to initiate a CAPA based on one quality event (e.g. one complaint, one MDR, one recall, one external audit observation, etc.) …. decisions should be commensurate with risk, including the extent of action required to address the quality event.”. Your firm’s management stated that there has not been one quality event in the three years of data reviewed for piston syringes that has resulted in CAPA.\n\nDuring the inspection our investigator noted that you initiated a Regulatory Assessment Change (RAC), K061275-01 to allow dimensional changes to the Medline Piston Syringes to improve the user experience by reducing the chance for cracked syringes and plunger pullout. Your firm’s management explained to our investigator that the RAC was an improvement and enhancement and not done to improve clinical outcomes, mitigate a known risk, or in response to an adverse event. Your firm’s design failure mode and effects analysis (DFMEA), SOP-00099-F-00004 for Medline piston syringe (K061275) lists among other things, piston syringes dimensions and fit as having an impact on product quality and functionality.\n\nThe DFMEA indicates that performance testing and finished product testing have reduced the risk as low as possible however your firm continues to receive complaints for loss of primary function among others. All complaints cannot be attributed to application user failures described in your firm’s application failure mode and effects analysis (aFMEA) SOP-00099-F-00005 for Medline piston syringe (K061275).\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with CAPA procedures. These actions encompass conducting a retrospective review of complaints, a reanalysis of complaints, revising procedures, and training staff members. Additionally, corrective actions are being created within the CAPA system for each respective observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\n4. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\n\nSpecifically, your firm’s Vendor Evaluation Procedure SOP-00003 has not been adequately established or maintained to ensure requirements, including quality requirements have been met by suppliers and contractors. For example, the Vendor Evaluation - Supplier Disposition Form for supplier “S” lacks a documented review of marketing clearance for products you distribute and\u002For further manufacture. There is no objective evidence to support the quality agreement requirement “Supplier shall only supply product to Medline that has the appropriate marketing clearance.”\n\nThe adequacy of your firm’s response dated February 12, 2024, cannot be determined at this time. The response notes that your firm has undertaken corrective actions to address the issue with purchasing controls to include revisions to purchasing control procedures, employee training, retrospective review of all Medline-branded syringes and syringe kit components, performing a review of active Medline-branded medical devices (non-syringes) and submitting a new 510(k) Premarket Notification for all sizes\u002Fmodels of Medline Piston Syringes. Additionally, corrective actions are being created within the CAPA system for the observation to decide if further remediation actions are necessary. However, the response does not furnish specific information regarding the results or outcomes of these corrective actions as they are still ongoing.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 677545 when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Rafael Padilla at 312-596-4212 or Rafael.padilla@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill\n\nProgram Division Director\n\nOffice of Medial Device and Radiological Health\n\nOperations (OMDRHO) Division 2 Central\n\nAnd\n\nKellie B. Kelm, Ph.D.\n\nActing Director\n\nOHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","medline-industries-lp-677545-03182024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-industries-lp-677545-03182024","2026-10-26T08:09:23.450135+00:00","2024-03-19","677545","James Boyle","2026-08-20T00:14:01.484+00:00","VIA UNITED PARCEL SERVICE","2024-03-18",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":18,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":57,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":71,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},137,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-28T04:00:00Z\">05\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-inc-724347-05282026\">Medline Inc\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-82\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. James Boyle \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Medline Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3 Lakes Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60093\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-82\u003C\u002Fp>\u003Cp>May 28, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Boyle:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medline Industries, LP, FEI 3003983334, at 1710 South Lakeside Drive, Waukegan, Illinois, from October 6 to 14, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 4, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is also specifically labeled for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your manufacturing process includes \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and sealed into the respective finished drug product packaging.\u003C\u002Fp>\u003Cp>Between June 2, 2023 and August 27, 2025, your firm isolated objectionable microorganisms (e.g., \u003Cem>Bacillus cereus (B. cereus)\u003C\u002Fem>) from \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug product samples on approximately nine occasions. You also recovered \u003Cem>B. cereus\u003C\u002Fem> in at least five samples taken from your manufacturing environment since January 2025. You failed to adequately investigate and implement corrective actions and preventive actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting held with your firm in May 2025.\u003C\u002Fp>\u003Cp>Further, your investigations into contaminated drug product samples identified \u003Cem>B. cereus\u003C\u002Fem> in your manufacturing environment, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> at your facility, as well as on \u003Cstrong>(b)(4)\u003C\u002Fstrong> at another Medline facility (Hartland), which supplies your bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Multiple investigations since 2023 have determined that \u003Cstrong>(b)(4)\u003C\u002Fstrong> are a root cause for the \u003Cem>B. cereus\u003C\u002Fem> contamination in your drug products.\u003C\u002Fp>\u003Cp>In your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” You suspended \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product production in October 2025. You also committed to verifying corrective actions and their effectiveness before notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including management controls, deviation investigations, and facility and process improvements.\u003C\u002Fp>\u003Cp>Your response is inadequate because you have not explained why your previous CAPA attempts were not successful. Additionally, your investigations failed to adequately identify the root causes of contamination in your drug products and the source of \u003Cem>B. cereus\u003C\u002Fem> contamination within your manufacturing environment, including from your bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response also states that you have not released any drug product batches with failing microbiological test results. However, finished product microbiological testing cannot be relied upon as sole justification to release drug product batches, as contamination is not uniformly distributed in a system and any given sample may not be representative of the type or level of contamination.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that may pose a patient safety hazard. Your manufacturing processes and cleanroom environments are inadequately designed to assure an ongoing state of control. It is your responsibility to design and control operations to prevent contamination of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Microbial contamination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> poses a significant risk of patient harm and adverse \u003Cstrong>(b)(4)\u003C\u002Fstrong> outcomes, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Thus, the use of manufacturing processes that render these drugs sterile is an integral part of ensuring safety of patients due to the vulnerability to \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your manufacturing processes, equipment, and facilities, including, but not limited to:\u003Cbr>o All human interactions within the cleanroom areas (e.g., risk reduction or elimination of manual interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the cleanroom area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support manufacturing operations, and all material transfers).\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to manufacturing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient manufacturing operations. Include comprehensive changes to the design of both your manufacturing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>An independent assessment by qualified experts of the various sterilization options that can be implemented for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products. Based on this assessment, provide a comprehensive plan and timeline to transition your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs to terminal sterilization, or implement aseptic processing of these products. In the event that you are considering continued use of processes that are inherently vulnerable to contamination issues, provide a detailed rationale justifying your scientific and public health basis, with particular attention to the unacceptable patient risks posed by your historical contamination problems.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including, but not limited to:\u003Cbr>o Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) was conducted\u003Cbr>o Assess sufficiency of review of past related investigations (deviations, failures) to identify potential associated causes or linkages\u003Cbr>o Evaluate adequacy of scope, rigor, staff competencies, scientific\u002Fanalytical foundation, and CAPA\u003Cbr>o Summary of findings of the assessment for each of the above elements.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups; failed to perform operations within specifically defined areas of adequate size; and failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.42(c) and 21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm isolated significant opportunistic pathogens, including \u003Cem>B. cereus\u003C\u002Fem>, in numerous samples of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug products and the manufacturing environment.\u003C\u002Fp>\u003Cp>You failed to establish appropriate design and control of your manufacturing operation to assure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products \u003Cstrong>(b)(4)\u003C\u002Fstrong> were suitable for their intended use. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting conducted with your firm in May 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Deficient Manufacturing Practices\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your manufacturing operators engaged in practices that pose significant contamination risk to \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, such as using cleaning tools without suitable gloves and then repeatedly touching the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Investigations by your firm identified objectionable aseptic behaviors as a root cause of \u003Cem>B. cereus\u003C\u002Fem> contamination in your products.\u003C\u002Fp>\u003Cp>Your manufacturing process involves \u003Cstrong>(b)(4)\u003C\u002Fstrong> manipulations including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug components, equipment, and scrap materials. These activities are particularly worrisome if your operations are not conducted and maintained in an aseptic manner (e.g., donning sterile gowning), or the drug product is not sterilized in its final packaging. It is essential that manufacturers establish robust manufacturing design and process control measures to prevent contamination throughout production operations. In addition to appropriate manufacturing facilities and processes, raw materials (e.g., components, containers, and closures) must also be suitable for their intended use.\u003C\u002Fp>\u003Cp>In your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” As noted above, you also state that you suspended production of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product in October 2025. You commit to verifying your corrective actions as effective prior to notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including corrections to cleanroom behaviors, cleaning and maintenance procedures, contamination controls, and retraining.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Inadequate Cleaning and Disinfection\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your manufacturing operators have routinely deviated from procedures for cleaning and disinfection of your drug manufacturing equipment, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example, numerous deviation investigations have noted operator failures to properly clean and disinfect your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and valves with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Notably, \u003Cstrong>(b)(4)\u003C\u002Fstrong> have been identified as a root cause for \u003Cem>B. cereus\u003C\u002Fem> contamination in your drug products since 2023.\u003C\u002Fp>\u003Cp>Establishing and following appropriate procedures for cleaning, disinfection, and whenever appropriate, sterilization is essential to ensuring product safety.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your proposed corrections are insufficient to remediate flawed facility and process design. You have unsuccessfully attempted similar corrective actions in the past.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An independent assessment and associated CAPA plan, following a thorough retrospective review of your cleaning, disinfection, and sterilization program, that includes appropriate remediations and timelines for completion. Provide a detailed summary of vulnerabilities in your processes and procedures relating to equipment cleaning, disinfection, and sterilization. Describe improvements to your program, including enhancements to cleaning and disinfection types and practices; addition or improvement of sterilization methods; and all other needed remediations.\u003C\u002Fli>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to a thorough independent assessment of the following with accompanying CAPA:\u003Cbr>o Suitability of actual practices based on a retrospective review and prospective observation of cleanroom operations\u003Cbr>o Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o Frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic behaviors and its support operations\u003Cbr>o Adequacy of written procedures\u003Cbr>o The risk assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality of your drugs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Repeat Observations at Multiple Sites\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA cited similar CGMP observations at other facilities in your company’s network, including inadequate investigations into OOS results at your Hartland, Wisconsin site. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>Your executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\u003Cp>For more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003983334 and ATTN: Philip Kreiter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-82\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. James Boyle\n\nRecipient Title\n\nChief Executive Officer\n\nMedline Inc\n\n3 Lakes Drive\n\nNorthfield, IL 60093\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-82\nMay 28, 2026\nDear Mr. Boyle:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Medline Industries, LP, FEI 3003983334, at 1710 South Lakeside Drive, Waukegan, Illinois, from October 6 to 14, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 4, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures (b)(4) for (b)(4) is also specifically labeled for (b)(4). Your manufacturing process includes (b)(4), and sealed into the respective finished drug product packaging.\nBetween June 2, 2023 and August 27, 2025, your firm isolated objectionable microorganisms (e.g., Bacillus cereus (B. cereus)) from (b)(4) finished drug product samples on approximately nine occasions. You also recovered B. cereus in at least five samples taken from your manufacturing environment since January 2025. You failed to adequately investigate and implement corrective actions and preventive actions (CAPA) to determine root causes and prevent recurrence of these repeated contamination incidents. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting held with your firm in May 2025.\nFurther, your investigations into contaminated drug product samples identified B. cereus in your manufacturing environment, including (b)(4) at your facility, as well as on (b)(4) at another Medline facility (Hartland), which supplies your bulk (b)(4). Multiple investigations since 2023 have determined that (b)(4) are a root cause for the B. cereus contamination in your drug products.\nIn your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” You suspended (b)(4) drug product production in October 2025. You also committed to verifying corrective actions and their effectiveness before notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including management controls, deviation investigations, and facility and process improvements.\nYour response is inadequate because you have not explained why your previous CAPA attempts were not successful. Additionally, your investigations failed to adequately identify the root causes of contamination in your drug products and the source of B. cereus contamination within your manufacturing environment, including from your bulk (b)(4). Your response also states that you have not released any drug product batches with failing microbiological test results. However, finished product microbiological testing cannot be relied upon as sole justification to release drug product batches, as contamination is not uniformly distributed in a system and any given sample may not be representative of the type or level of contamination.\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that may pose a patient safety hazard. Your manufacturing processes and cleanroom environments are inadequately designed to assure an ongoing state of control. It is your responsibility to design and control operations to prevent contamination of your (b)(4).\nMicrobial contamination of (b)(4) drugs used for (b)(4) poses a significant risk of patient harm and adverse (b)(4) outcomes, (b)(4). Thus, the use of manufacturing processes that render these drugs sterile is an integral part of ensuring safety of patients due to the vulnerability to (b)(4) infection.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your manufacturing processes, equipment, and facilities, including, but not limited to:\no All human interactions within the cleanroom areas (e.g., risk reduction or elimination of manual interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the cleanroom area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel Flow and Material Flow (movement throughout all rooms used to conduct and support manufacturing operations, and all material transfers).\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe comprehensive improvements to be made to manufacturing operation design and control at your facility and explain how this CAPA plan will robustly remediate your deficient manufacturing operations. Include comprehensive changes to the design of both your manufacturing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nAn independent assessment by qualified experts of the various sterilization options that can be implemented for your (b)(4) products. Based on this assessment, provide a comprehensive plan and timeline to transition your (b)(4) drugs to terminal sterilization, or implement aseptic processing of these products. In the event that you are considering continued use of processes that are inherently vulnerable to contamination issues, provide a detailed rationale justifying your scientific and public health basis, with particular attention to the unacceptable patient risks posed by your historical contamination problems.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent, retrospective review of all critical investigations (including each in-process, release, and stability test specification failure) for the last three years as of the date of this letter. Evaluate the adequacy of each investigation, including, but not limited to:\no Determine whether a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) was conducted\no Assess sufficiency of review of past related investigations (deviations, failures) to identify potential associated causes or linkages\no Evaluate adequacy of scope, rigor, staff competencies, scientific\u002Fanalytical foundation, and CAPA\no Summary of findings of the assessment for each of the above elements.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups; failed to perform operations within specifically defined areas of adequate size; and failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.42(c) and 21 CFR 211.67(b)).\nYour firm isolated significant opportunistic pathogens, including B. cereus, in numerous samples of your (b)(4) finished drug products and the manufacturing environment.\nYou failed to establish appropriate design and control of your manufacturing operation to assure your (b)(4) drug products (b)(4) were suitable for their intended use. This issue was cited on the previous Form FDA 483 issued to your firm in January 2025 and subsequently discussed during the most recent regulatory meeting conducted with your firm in May 2025.\nDeficient Manufacturing Practices\nYour manufacturing operators engaged in practices that pose significant contamination risk to (b)(4) drug products, such as using cleaning tools without suitable gloves and then repeatedly touching the (b)(4). Investigations by your firm identified objectionable aseptic behaviors as a root cause of B. cereus contamination in your products.\nYour manufacturing process involves (b)(4) manipulations including the (b)(4) drug components, equipment, and scrap materials. These activities are particularly worrisome if your operations are not conducted and maintained in an aseptic manner (e.g., donning sterile gowning), or the drug product is not sterilized in its final packaging. It is essential that manufacturers establish robust manufacturing design and process control measures to prevent contamination throughout production operations. In addition to appropriate manufacturing facilities and processes, raw materials (e.g., components, containers, and closures) must also be suitable for their intended use.\nIn your response, you acknowledge “that the FDA inspection identified gaps in adherence to the corrective actions and cGMP’s.” As noted above, you also state that you suspended production of the (b)(4) drug product in October 2025. You commit to verifying your corrective actions as effective prior to notifying FDA of your intent to resume production. You also refer to several previously initiated CAPA in response to the microbiological contamination incidents, including corrections to cleanroom behaviors, cleaning and maintenance procedures, contamination controls, and retraining.\nInadequate Cleaning and Disinfection\nYour manufacturing operators have routinely deviated from procedures for cleaning and disinfection of your drug manufacturing equipment, including (b)(4) for (b)(4) drug products. For example, numerous deviation investigations have noted operator failures to properly clean and disinfect your (b)(4) and valves with (b)(4). Notably, (b)(4) have been identified as a root cause for B. cereus contamination in your drug products since 2023.\nEstablishing and following appropriate procedures for cleaning, disinfection, and whenever appropriate, sterilization is essential to ensuring product safety.\nYour response is inadequate. Your proposed corrections are insufficient to remediate flawed facility and process design. You have unsuccessfully attempted similar corrective actions in the past.\nIn response to this letter, provide:\nAn independent assessment and associated CAPA plan, following a thorough retrospective review of your cleaning, disinfection, and sterilization program, that includes appropriate remediations and timelines for completion. Provide a detailed summary of vulnerabilities in your processes and procedures relating to equipment cleaning, disinfection, and sterilization. Describe improvements to your program, including enhancements to cleaning and disinfection types and practices; addition or improvement of sterilization methods; and all other needed remediations.\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to a thorough independent assessment of the following with accompanying CAPA:\no Suitability of actual practices based on a retrospective review and prospective observation of cleanroom operations\no Deficiencies in production management oversight, and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no Frequency and depth of quality unit oversight (e.g., audit, ad hoc, daily interactions) of aseptic behaviors and its support operations\no Adequacy of written procedures\no The risk assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality of your drugs.\nRepeat Observations at Multiple Sites\nFDA cited similar CGMP observations at other facilities in your company’s network, including inadequate investigations into OOS results at your Hartland, Wisconsin site. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.\nYour executive management remains responsible for fully resolving all deficiencies and ensuring ongoing CGMP compliance. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\nFor more information about handling failing, out-of-specification, out-of-trend, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003983334 and ATTN: Philip Kreiter.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Medline Inc","medline-inc-724347-05282026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedline-inc-724347-05282026","2026-10-26T08:09:23.37043+00:00","2026-06-02","724347","Drugs","Mr. James Boyle","2026-08-19T04:39:18.457+00:00","Via Electronic Mail - Return Receipt Requested","320-26-82","2026-05-28",3,{"510k":75,"classification":76,"enforcement":77,"event":78,"event_backfill":79,"pma":80,"warning_letter":81},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]